BioHarvest Sciences Inc., a company specializing in Botanical Synthesis technology, reported a significant increase in its first quarter 2025 financial results. Revenues surged by 47% year-over-year to $7.9 million, surpassing management's guidance. This growth was primarily driven by the success of the VINIA® product line, which expanded its active subscriber base to over 50,000 as of February 2025. Gross profit for the quarter rose by 53% to $4.6 million, representing 58.5% of total revenue, compared to $3.0 million or 56.2% in the same period the previous year. The improvement in gross margin was attributed to enhanced manufacturing scale and yields. Looking forward, BioHarvest anticipates continued expansion in its Products and Services business units, aiming to grow the "VINIA® inside" product lines and subscriber bases, along with adding new CDMO partners. The company remains focused on leveraging its Botanical Synthesis platform to meet rising global consumer health and wellness trends.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.